SINOPHARM TECH announced its annual performance, with a loss attributable to shareholders of approximately HKD 900,000, a significant decrease of about 95% year-on-year
SINOPHARM TECH announced its annual performance for the period ending June 30, 2025, with revenue of approximately HKD 61.3 million, an increase of about 48% year-on-year. The loss attributable to shareholders was approximately HKD 900,000, a significant decrease of about 95% year-on-year. The loss per share was HKD 0.19. The revenue growth was mainly due to increased demand in the health products market and improved supply chain service efficiency. The board pointed out that the reasons for the improvement in financial performance include growth in gross profit, cost control, and reduced financing costs
According to the Zhitong Finance APP, SINOPHARM TECH (08156) announced its annual performance for the year ending June 30, 2025, with revenue of approximately HKD 61.3 million, an increase of about 48% year-on-year. The loss attributable to shareholders was approximately HKD 900,000, a significant decrease of about 95% year-on-year. The loss per share was HKD 0.19.
The announcement stated that the revenue growth was mainly due to increased demand in the health products market and improved operational efficiency in supply chain services, highlighting the effectiveness of the company's strategic focus on these core business areas.
The board believes that the group's financial performance significantly improved this year mainly due to the net impact of the following factors: (i) a year-on-year increase in gross profit of approximately HKD 9.2 million or 184% due to business improvement; (ii) strengthened cost control over administrative and operational expenses; (iii) loan capitalization income of approximately HKD 3.9 million this year; and (iv) reduced financing costs due to loan capitalization this year
